Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Report of the Board of Directors' Audit Committee on the Evaluation of the Accounting Firm's Performance in 2025 and Fulfillment of Supervisory Responsibilities
In accordance with the "Company Law of the People's Republic of China," "Securities Law of the People's Republic of China," "Measures for the Selection and Appointment of Accounting Firms by State-owned Enterprises and Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 1 - Norms for Operation of Main Board Listed Companies," and other relevant laws, regulations, normative documents, and the "Articles of Association," the Audit Committee of the Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") has diligently performed its duties and fulfilled its responsibilities. The report of the Audit Committee of the Board of Directors on the evaluation of the accounting firm's performance in 2025 and the fulfillment of supervisory responsibilities is as follows:
I. Basic Information of the Accounting Firm for the 2025 Annual Audit
(I) Basic Information of the Accounting Firm
Ernst & Young Hua Ming was established in September 1992 and completed its localization reform in August 2012, transforming from a Sino-foreign joint venture limited liability partnership into a special general partnership. Ernst & Young Hua Ming is headquartered in Beijing, with its registered address at 17/F, Ernst & Young Tower, Oriental Plaza, Dongcheng District, Beijing, Room 01-12.